281 related articles for article (PubMed ID: 22277034)
1. [Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management].
Horký K
Vnitr Lek; 2011 Dec; 57(12):1012-6. PubMed ID: 22277034
[TBL] [Abstract][Full Text] [Related]
2. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
3. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone and end-organ damage.
Marney AM; Brown NJ
Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
[TBL] [Abstract][Full Text] [Related]
6. Interactions of high salt intake and the response of the cardiovascular system to aldosterone.
Conlin PR
Cardiol Rev; 2005; 13(3):118-24. PubMed ID: 15831143
[TBL] [Abstract][Full Text] [Related]
7. Induction of cardiac fibrosis by aldosterone.
Lijnen P; Petrov V
J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
Pasquale PD; Stefano GD; Paterna S
Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone, mineralocorticoid receptor, and heart failure.
Messaoudi S; Azibani F; Delcayre C; Jaisser F
Mol Cell Endocrinol; 2012 Mar; 350(2):266-72. PubMed ID: 21784127
[TBL] [Abstract][Full Text] [Related]
10. Role of aldosterone in left ventricular hypertrophy in hypertension.
Matsumura K; Fujii K; Oniki H; Oka M; Iida M
Am J Hypertens; 2006 Jan; 19(1):13-8. PubMed ID: 16461184
[TBL] [Abstract][Full Text] [Related]
11. Vascular actions of aldosterone.
Briet M; Schiffrin EL
J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
[TBL] [Abstract][Full Text] [Related]
12. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
13. Expanding view of aldosterone action, with an emphasis on rapid action.
Vinson GP; Coghlan JP
Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):410-6. PubMed ID: 20409082
[TBL] [Abstract][Full Text] [Related]
14. [Aldosterone blockade in essential hypertension].
Venco A; Grandi AM
Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
[TBL] [Abstract][Full Text] [Related]
16. [Aldosterone and cardiovascular diseases, more than water and salt retention].
Duprez D
Verh K Acad Geneeskd Belg; 2002; 64(3):225-32. PubMed ID: 12238244
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone as a cardiovascular risk factor.
Rossi G; Boscaro M; Ronconi V; Funder JW
Trends Endocrinol Metab; 2005 Apr; 16(3):104-7. PubMed ID: 15808807
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
Galuppo P; Bauersachs J
Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.
Schrier RW; Masoumi A; Elhassan E
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1132-40. PubMed ID: 20448074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
